Oct 23, 2026 01:47PM
Oct 1, 2026 07:13AM
Aug 18, 2026 02:12AM
Jul 1, 2026 09:15AM
May 27, 2026 02:25AM
May 25, 2026 10:52PM
May 25, 2026 10:52PM Hansa Biopharma Announces Late-Breaking Abstract from ConfIdeS Phase 3 Trial Selected for Oral Presentation at ATC 2026
May 19, 2026 02:20AM
Mar 26, 2026 03:19AM
Mar 4, 2026 06:25PM
Feb 18, 2026 02:28PM
Feb 11, 2026 01:29AM
Jan 22, 2026 07:38AM
Dec 19, 2025 02:43PM Hansa Biopharma Submits BLA to FDA for Imlifidase in desensitization for Kidney Transplantation
Oct 30, 2025 02:16AM
Sep 24, 2025 02:07PM
Sep 24, 2025 02:06PM
Jul 17, 2025 01:43AM
Jul 17, 2025 01:43AM
Mar 21, 2025 10:15AM
Feb 6, 2025 01:34AM Hansa Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results
Jan 7, 2025 11:19AM
Dec 5, 2024 10:24AM
Oct 17, 2024 01:17AM
Jul 18, 2024 01:34AM
May 31, 2024 08:12AM
May 21, 2024 01:18AM
Feb 2, 2024 01:28AM Hansa Biopharma Year-end report January-December 2023
Dec 7, 2023 01:21AM
Jul 20, 2023 01:31AM
May 30, 2023 02:23AM
Mar 31, 2023 02:17AM
Nov 2, 2022 10:54PM
Oct 20, 2022 03:00AM
Jul 19, 2022 02:12AM Hansa Biopharma half year report 2022
Jul 18, 2022 04:46PM
May 30, 2022 11:06AM
Apr 21, 2022 02:38AM
Apr 7, 2022 02:17AM
Feb 3, 2022 02:17AM
Jan 9, 2022 11:52AM
Dec 29, 2021 02:14AM Hansa Biopharma enrolls first patient in U.S. randomized, controlled pivotal trial of imlifidase in highly sensitized kidney transplant patients
Nov 15, 2021 02:41AM
Oct 21, 2021 02:37AM
Apr 22, 2021 02:17AM
Apr 9, 2021 02:42AM
Apr 8, 2021 02:36AM
Jan 11, 2021 02:16AM
Oct 22, 2020 02:14AM Hansa Biopharma interim report Jan-Sep 2020
Sep 1, 2020 01:59PM

336,255 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All